Final Results

Angle PLC
06 July 2005


For Immediate Release                                               6 July 2005




                                   ANGLE plc
                           ('ANGLE' or the 'Company')

              Preliminary Results for the year ended 30 April 2005

ANGLE plc, the intellectual property and technology commercialisation company,
announces its preliminary results for the year ended 30 April 2005.

Financial Highlights

•   Turnover increased by 44% to £4.13 million (2004: £2.87 million).

•   Consulting and Management operating profit increased by 22% to £0.52 million 
    (2004: £0.43 million).

•   Investment to establish and develop new Ventures increased by 251% to 
    £3.02 million (2004: £0.86 million) comprising Ventures operating
    costs expensed in the profit and loss account of £1.79 million (2004: £0.68
    million) and increase in fixed asset investments on the balance sheet of 
    £1.24 million (2004: £0.19 million).

•   Loss before tax was £2.35 million.  The loss is stated after new Ventures 
    development costs as above and a provision for diminution in value of 
    current asset investments of £1.57 million (2004: nil).  In 2004 the
    profit before tax was £2.33 million, which included profit of £2.31 million 
    on disposal of investments.

•   Basic loss per share of 13.87p (2004: profit 20.43p).

•   Cash at bank at year end £5.55 million (2004: £8.25 million).

•   Consulting and Management businesses entered new financial year with strong 
    sold order book of £8.98 million (2004: £3.23 million).


Operational Highlights

•   Consulting and Management won a major new Qatar Science & Technology Park 
    contract worth over £6m over 3 years.

•   Four new Progeny(R) companies formed: Contrasoft, Customiser, Geomerics and 
    Novocellus each offering the potential to address major worldwide markets in 
    software testing, internet personalisation, computer graphics and IVF embryo 
    viability respectively.

•   Good progress made by Progeny(R) companies: Acolyte Biomedica, NeuroTargets 
    and Provexis. In particular, Acolyte Biomedica has completed development of 
    its MRSA testing product and made first sales in May 2005. Provexis has 
    progressed product development and clinical trials of its cardio-vascular 
    health drink, Sirco, to be launched in Q4 2005.

•   Flotation of Provexis completed in June 2005 through a reverse acquisition 
    of Nutrinnovator Holdings, generating a gain in valuation for ANGLE of 
    £2.00 million at the placing price.

•   New Directors of Ventures appointed in the UK and US and teams strengthened 
    with new recruits.

•   Negotiations in progress with major technology corporates, research 
    establishments and universities for commercialisation of their intellectual 
    property.



Hance Fullerton, Chairman, commented:

'ANGLE has made good progress in the growth of its business during the year.
The Consulting and Management businesses have delivered increased revenue and
profits and secured a major new contract in Qatar worth in excess of £6 million.

Our Ventures teams have expanded in the UK and US and relationships have been
further developed with leading technology organisations.  Good progress has been
made in evaluating and developing new venture propositions.  Work was completed
on the development of four new Progeny(R) companies during the year and the
existing Progeny(R) companies were developed against their milestones towards
realising value for our shareholders.  Notably, the flotation of Provexis in
June 2005, generated a substantial gain in valuation for ANGLE once again
demonstrating the value of ANGLE's Progeny(R) process.'

Enquiries:
ANGLE plc                                                 01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive
Ian Griffiths, Finance Director

Buchanan Communications                                   020 7466 5000
Richard Darby, Suzanne Brocks, James Strong


A presentation for analysts will take place today at 10:00am at the offices of
Buchanan Communications, 107 Cheapside, London, EC2V 6DN.  Please call Buchanan
Communications for more details.

Notes to Editors

Founded in 1994, ANGLE is an international venture management and consulting
group focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients. ANGLE is listed on AIM
(AGL.L); further information can be found on www.ANGLEplc.com



CHAIRMAN'S STATEMENT

Introduction

During the year ended 30 April 2005, ANGLE made good progress in developing its
business in accordance with plans set out at flotation in March 2004.

Strong growth of the Consulting and Management businesses was achieved and the
Ventures business was scaled up using the monies raised at the flotation.
Investments were made to establish three new Progeny(R) Companies in the year
with a fourth announced immediately after the year end.

Strong progress was made by Acolyte Biomedica, NeuroTargets and Provexis against
their milestones during the year, with a notable success being Provexis'
flotation completed in June 2005.

Results

In the year ended 30 April 2005, ANGLE increased turnover by 44% to £4.13
million (2004: £2.87 million).  The loss before tax was £2.35 million, which was
principally made up of the following elements:

•  Increased profit before tax on the Consulting and Management businesses to 
   £0.52 million (2004: £0.43 million), up by 22%;

•  Increased investment to establish and develop new Ventures expensed in the 
   profit and loss account of £1.79 million (2004: £0.68 million) up 164%;

•  A provision for diminution in the value of investments of £1.57 million 
   resulting from our holding in Corpora plc;

•  Interest of £0.24 million (2004: £0.05 million).

In 2004 the profit before tax was £2.33 million, which included profit of £2.31
million on disposal of Exago to Corpora plc.  The basic loss per share was
13.87p (2004: profit 20.43p).

Finance

At the year end, ANGLE had cash at bank of £5.55 million (2004: £8.25 million).
The reduction was principally planned investment to establish and develop new
Ventures, which increased by 251% to £3.02 million (2004: £0.86 million)
comprising Ventures operating costs expensed in the profit and loss account of
£1.79 million (2004: £0.68 million) and increase in fixed asset investments on
the balance sheet of £1.24 million (2004: £0.19 million).

In addition to cash balances, ANGLE held a quoted investment valued at £0.88
million at the year end relating to its holdings in Corpora plc.  Subsequent to
the year end, completion of the Provexis flotation led to ANGLE holding an
additional quoted investment in Provexis plc valued at £3.47 million at the
placing price, which included a gain in valuation of £2.00 million.

Progeny(R) Companies

Significant progress has been made in expanding our Ventures capabilities and
activities.  Senior staff have been appointed to lead and develop new Ventures
in both the UK and US markets, bringing experience from major corporate,
management consulting and venture capital roles.

During the year, we completed work on establishing four new Progeny(R)
Companies, three of which were founded in the year and the fourth immediately
thereafter.  These companies address large markets in software testing, internet
personalisation, computer graphics and IVF embryo viability.

We are in negotiation with several major corporates and universities in the UK
and US to agree the basis for commercialisation of their intellectual property.

Of our four Progeny(R) companies existing at the start of the financial year,
three developed well during the year according to their agreed milestones.  Of
particular note, was the work undertaken during the year towards the flotation
of Provexis, which completed in June 2005.  Development of the fourth company,
IDR Therapeutics, was terminated when market evaluation indicated that there
were better alternative opportunities available to us.

Strategy and Outlook

ANGLE's objective is to achieve profitable long term capital growth for its
shareholders through the successful combination of its Consulting and Management
businesses with the establishment and development of a portfolio of Progeny(R)
Companies in a range of technology sectors.  The Group's access to intellectual
property combined with its highly experienced management team puts it in a
strong position to fulfil this objective over the next few years.

The Consulting and Management order book remains strong at £8.98 million at 30
April 2005 (2004: £3.23 million), with particularly strong growth forecast in
the Middle East as a result of a major new contract in Qatar.

The outlook for the current financial year is encouraging.  Since the start of
the financial year, we have already made a number of important announcements
including the:

•       flotation of Provexis through a reverse acquisition of Nutrinnovator 
        Holdings plc raising new equity of £5.9m from new funding and the
        conversion of loans.  Provexis' leading product Sirco, containing active
        ingredient FruitFlow(R) (previously known as CardioFlow(R)) for 
        maintaining cardiovascular health, is scheduled to be launched in UK 
        supermarkets in the final quarter of 2005;

•       launch of the BacLite(R) MRSA detection product by Acolyte Biomedica 
        with sales to Barts and the London NHS Trust and Salisbury District
        Hospital.  The product has been well received and the company expects 
        strong demand.  Separately Acolyte signed a joint venture with Scottish 
        National Blood Transfusion Service to develop a test for bacterial 
        contaminants in blood.

•       formation of a new Progeny(R) Company, Geomerics, to commercialise 
        intellectual property developed by academics from the University
        of Cambridge for application in high speed computer games graphics.

The pipeline of potential Progeny(R) Companies is strong and presents
significant opportunities for ANGLE to further expand its Venture development
activities.

I would like to thank all members of the ANGLE team for their efforts in
delivering a strong performance in our first year as a public company.  We have
an exceptional team, and I am grateful for all their hard work, enthusiasm and
commitment to the business. I look forward to working with them in the year
ahead.


Hance Fullerton
Chairman
5 July 2005



OPERATIONS SUMMARY

Consulting and Management

ANGLE has built profitable Consulting and Management businesses in the UK, US
and Middle East, generating revenue and providing expert in-house staff
capability as well as the opportunity to build important relationships with
corporates, government research establishments and universities.  The
relationships with owners of intellectual property are a key channel for the
Group to identify and exploit opportunities to commercialise intellectual
property using its proprietary Progeny(R) process.

The Consulting and Management businesses have performed strongly during the
year.  Fees increased 47% to £3.90 million (2004: £2.66 million) resulting in a
profit up 22% at £0.52 million (2004: £0.43 million).  A number of major
contracts were secured during the year and the order book is strong at £8.98
million (2004: £3.23 million).

During the year, ANGLE secured its largest ever fee-for-service contract, to
manage the Qatar Science & Technology Park (QSTP) until March 2009.  The
contract is worth over £6m in addition to the existing Qatar contracts.   ANGLE
is responsible for the effective establishment and operation of the QSTP,
placing us at the centre of one of the world's most ambitious technology
commercialisation projects.  We will be leading the research and
commercialisation process in Qatar through a raft of QSTP programmes including
the creation and growth of new technology companies, establishment of a venture
capital fund, and development of an entrepreneurship training and mentoring
program.

Ventures

The Ventures business made good progress during the year.  The management teams
in the UK and US were both strengthened with new recruits, and, in accordance
with our plans set out at the time of flotation,  investment to establish and
develop new Ventures was increased 251% to £3.02 million (2004: £0.86 million).
This comprised Ventures operating costs expensed in the profit and loss account
of £1.79 million (2004: £0.68 million) and an increase in fixed asset
investments on the balance sheet of £1.24 million (2004: £0.19 million).

The pipeline of new opportunities available to ANGLE has been significantly
developed.  An example of this was the agreement with Ben Franklin Technology
Partners of Southeastern Pennsylvania (BFTP), an internationally recognised
economic development organisation, to advance the growth of technology-based
companies in the Greater Philadelphia region.  It is contemplated that ANGLE
will commit $5 million over five years for funding new technology spin-outs that
meet its Progeny(R) requirements.  This funding will be matched by BFTP on a
non-dilutive basis, thus doubling the leverage on ANGLE funds for creating
Progeny(R) companies.

The Greater Philadelphia region is home to many of the world's most renowned
academic institutions including the University of Pennsylvania - one of the
leading research universities in the United States.   Collectively, the region's
academic institutions attract more than $1 billion of research funding per
annum, generating more than 200 patent applications per year.   The region is
well recognised as a global leader in the bio-pharma and medical research arena.
ANGLE will serve as BFTP's preferred commercialisation partner for
technologies from universities, colleges and related institutions in the region.

This agreement demonstrates the benefit ANGLE obtains from the combination of
its Consulting and Management businesses with its Ventures business.  ANGLE's
relationship with BFTP has developed from successful consulting work in
Pennsylvania, including the development of the strategy for nanotechnology in
the Commonwealth of Pennsylvania.

During the year, work was undertaken on establishing four new Progeny(R)
Companies:

•        ContraSoft: a software testing product company commercialising 
         technology developed by a corporate VP of R&D and University of
         Texas academic to improve productivity, reduce costs and improve 
         quality in the software testing process.

•        Customiser: an internet personalisation company founded to 
         commercialise intellectual property generated by a Cambridge team of
         psychologists and University pattern recognition experts to improve 
         on-line advertising and sales.

•        Geomerics: a computational graphics company founded just after the year 
         end to commercialise intellectual property developed by a team of
         leading academics from the University of Cambridge, Colorado School of 
         Mines and Arizona State University for application in high speed 
         computer games graphics.

•        Novocellus: an IVF diagnostic company founded to commercialise 
         revolutionary technology from University of York for non-invasive
         testing of the viability of IVF embryos.

Each of these new Progeny(R) Companies offer the potential to address major
worldwide markets with differentiated products protected by intellectual
property.  The development of these companies is carefully controlled using
ANGLE's Progeny(R) process to minimise the development risk and enhance the
return to all the shareholders.  Substantial capital returns are expected to
accrue to ANGLE shareholders from these new Progeny companies within three to
five years.

Good progress was made with ANGLE's existing Progeny(R) companies.  Most
notably, work during the year resulted in the flotation on AIM of Provexis via a
reverse acquisition of Nutrinnovator Holdings plc raising £5.9 million through a
placing and the conversion of loans.   Since the flotation was completed in June
2005, the financial impact of the transaction is not shown in ANGLE's accounts
to 30 April 2005.

Provexis was founded by ANGLE in 2000, using the Progeny(R) process, as a joint
venture with the Rowett Institute (a leading human nutrition research centre).
ANGLE's cost of investment on the balance sheet to develop Provexis using the
Progeny(R) process is £0.46 million.  At the placing price, this original
investment is valued at £2.13 million representing a multiple on investment of
4.6 times, an increase of £1.67 million over cost.  In addition, ANGLE provided
Provexis with convertible loan funding of £0.50 million in February 2005.  This
loan has been converted into new shares in Provexis plc valued at £0.83 million
at the placing price, representing a multiple on investment of 1.7 times and an
increase of £0.33 million over cost.  The overall gain in valuation to ANGLE
from the transaction is £2.00 million at the placing price.

ANGLE believes that the value of Provexis may increase substantially if Provexis
is successful in its launch of Sirco and has therefore invested £0.50 million in
the placing.  Following the placing and completion of the reverse takeover,
ANGLE holds 24.8% of Provexis plc's issued share capital.

ANGLE currently holds investments in eight companies, which it has developed
using its established Progeny(R) process.  Provexis is the second successful
transaction for ANGLE's venture companies since ANGLE's flotation in March 2004
and further demonstrates the value of ANGLE's Progeny(R) process.

In addition to work on Provexis' flotation, progress has also been made during
the year with the Progeny(R) companies established before ANGLE's flotation,
notably:

•        Acolyte Biomedica has completed the development of its MRSA testing 
         product and made its first sales of this product in May 2005.
         Independent hospital analysis of the product has been highly favourable 
         and market demand looks promising;

•        NeuroTargets has progressed its nerve injury and pain treatments and 
         secured an alliance with BioFocus plc aimed at discovering treatments 
         for nerve injury and pain;

•        Provexis has progressed product development and clinical trials of 
         Sirco, its cardio-vascular health drink containing active ingredient
         FruitFlow(R) (formerly known as CardioFlow(R)) and has announced plans 
         for the launch of the drink in the final quarter of 2005.

During the year, a detailed evaluation was undertaken of the market prospects
for Progeny(R) company, IDR Therapeutics.  It was concluded that the market
dynamic for IDR's product offering had changed with the likely impact that the
company would require a significantly increased level of investment over a
longer timescale before a return would be achieved.  Under these new
circumstances, the development of IDR Therapeutics no longer met our
requirements for investment under the Progeny(R) process.  Accordingly the
programme was terminated.  The cost of investment was £0.14 million, all of
which had previously been expensed through the profit and loss account.

Whilst it was disappointing to terminate the IDR programme, the strength of the
Progeny(R) process was demonstrated through identification of a potential
problem in advance of a major financial investment.  Where problems are
identified in the future with other Progeny(R) companies, these will be
similarly terminated with the minimum investment from ANGLE having been
committed.

The share price of Corpora PLC, the AIM listed company in which ANGLE holds
shares following the sale of its Progeny(R) company Exago to Corpora, has
regrettably fallen significantly during the year resulting in the need for an
increase in the provision for the diminution in value of investments to £1.57
million.  Even after this write down, ANGLE's original investment is still
valued at £0.85 million at the year end which is 4.0 times cost.  On a more
positive note, Corpora has recently completed a £3m placing to fund expansion
and announced software product sales to Microsoft and EDS.

The Company's ongoing strategy is to create more Progeny(R) companies in the
biosciences, electronics, optronics, IT, materials, nanotechnology and software
sectors.  At the year end, the pipeline for further Venture opportunities was
strong.  ANGLE's business model, high calibre management and its Progeny(R)
process have been recognised by many potential technology partners as bridging a
critical gap in exploiting their intellectual property.  As a result ANGLE is
evaluating new Venture opportunities with several of the UK's and US's top
technology universities, key research organisations and FTSE 100 / Fortune 500
businesses.

ANGLE's business is scaleable, well diversified into international markets and
benefits from a portfolio of companies specialising in a number of different
sectors. This diversity and flexibility is key to ANGLE's ongoing strength and
stability.

With a solid performance underpinning its activities, a strong sold order book
going forward and many exciting and profitable venture opportunities on the
horizon, ANGLE is facing the future with confidence and optimism.



ANGLE PLC
CONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 30 APRIL 2005

                                                            Note               2005                2004
                                                                                  £                   £

Turnover
Consulting and Management                                                 3,897,714           2,656,553
Ventures                                                                    234,437             219,257
                                                                          4,132,151           2,875,810
Operating costs
Consulting and Management                                               (3,375,944)         (2,228,087)
Ventures                                                                (1,785,400)           (674,918)
                                                                        (5,161,344)         (2,903,005)
Other operating income
Ventures
Profit on disposal of investments                                                 -           2,309,281

Operating profit / (loss)
Consulting and Management                                                   521,770             428,466
Ventures
Operating loss                                                          (1,550,963)           (455,661)
Profit on disposal of investments                                          _______-           2,309,281
                                                                        (1,550,963)           1,853,620

                                                                        (1,029,193)           2,282,086
Provision for diminution in value of
current asset investments                                               (1,566,372)                   -

Net interest                                                                242,184              46,384
                                                                          _________           _________
Profit / (loss) on ordinary activities
before taxation                                                         (2,353,381)           2,328,470

Tax on profit / (loss) on ordinary activities                  3             37,850            (37,850)
                                                                          _________           _________

Retained profit / (loss) for the year                                   (2,315,531)           2,290,620
                                                                         ==========          ==========
Earnings / (loss) per share                                    4
Basic (pence per share)                                                     (13.87)               20.43
Diluted (pence per share)                                                   (13.87)               19.45


The profit and loss account has been prepared on the basis that all operations
are continuing operations.



ANGLE PLC

CONSOLIDATED STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
FOR THE YEAR ENDED 30 APRIL 2005
                                                             2005            2004
                                                                £               £

Retained profit / (loss) for the year                 (2,315,531)       2,290,620

Currency translation differences                         (42,990)        (26,647)
                                                        _________       _________
Total gains and losses recognised in the year         (2,358,521)       2,263,973
                                                       ==========      ==========


ANGLE PLC

CONSOLIDATED BALANCE SHEET
AS AT 30 APRIL 2005
                                                         Note               2005               2004
                                                                               £                  £

Fixed assets
Tangible assets                                                           52,742             31,959
Investments                                                            1,755,779            516,782
                                                                       _________           ________
                                                                       1,808,521            548,741
Current assets
Investments                                                              881,805          2,398,177
Debtors - due within one year                                            847,584            625,503
Debtors - due after one year                                             239,570            239,570
Cash at bank and in hand                                               5,548,638          8,246,871
                                                                       _________           ________
                                                                       7,517,597         11,510,121
Creditors: amount falling due
within one year                                                        (686,585)        (1,063,116)
                                                                       _________           ________
Net current assets                                                     6,831,012         10,447,005
                                                                       _________           ________
Total assets less current liabilities                                  8,639,533         10,995,746

Creditors: amounts falling due
after more than one year                                                 (1,316)            (6,354)
                                                                       _________           ________
Net assets                                                             8,638,217         10,989,392
                                                                      ==========          =========

Capital and reserves
Called up share capital                                                1,670,648          1,669,648
Share premium account                                                  7,543,677          7,537,331
Profit and loss account                                              (3,129,464)          (770,943)
Other reserves                                                         2,553,356          2,553,356
                                                                       _________           ________
Shareholders' funds - equity interests                      5          8,638,217         10,989,392
                                                                      ==========          =========



ANGLE PLC

CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 APRIL 2005

                                                                                2005                2004
                                                                                   £                   £

Net cash inflow / (outflow) from operating activities                    (1,537,704)              48,592

Returns on investment and servicing of finance
Interest received                                                            246,936              10,960
Interest paid                                                                (3,262)             (7,307)
                                                                             _______             _______
Net cash inflow from returns on investment
and servicing of finance                                                     243,674               3,653

Capital expenditure and financial investment
Payments to acquire tangible fixed assets                                   (49,177)            (15,218)
Proceeds on disposal of tangible fixed assets                                      -                 650
Expenditure on investments                                               (1,288,997)           (106,317)
                                                                             _______             _______
Net cash outflow for capital expenditure                                 (1,338,174)           (120,885)
and financial investment

Net cash outflow from acquisitions and disposals                                   -                   -

Equity dividends paid                                                              -                   -
                                                                             _______             _______
Net cash outflow before management
of liquid resources and financing                                        (2,632,204)            (68,640)


Financing
Net proceeds from issue of ordinary share capital                           (69,241)           8,269,775
Capital element of finance lease contracts                                  (10,538)            (20,212)
                                                                            ________            ________
Net cash inflow / (outflow) from financing                                  (79,779)           8,249,563
                                                                           _________            ________

Increase / (decrease) in cash in the year                                (2,711,983)           8,180,923
                                                                          ==========           =========



ANGLE PLC

NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 APRIL 2005

C1 Reconciliation of operating loss to net cash outflow from operating
activities

                                                                                  2005              2004
                                                                                     £                 £

Operating profit / (loss)                                                  (1,029,193)         2,282,086
Depreciation of tangible fixed assets                                           27,244            30,823
Loss / (profit) on disposal of tangible fixed assets                                 -               118
Exchange differences                                                          (42,664)                 -
Loss / (profit) on disposal of fixed assets investments                              -       (2,398,177)
(Increase) / decrease in debtors                                             (223,573)         (332,361)
Increase / (decrease) in creditors within one year                           (269,518)           466,103
                                                                             _________          ________
Net cash inflow / (outflow) from operating activities                      (1,537,704)            48,592
                                                                            ==========         =========

C2  Analysis of net funds


                                                             1 May          Cash flow           30 April
                                                              2004                                  2005

                                                                 £                  £                  £
Net cash:
Cash at bank and in hand                                 8,246,871        (2,698,233)          5,548,638
Overdraft                                                        -           (13,750)           (13,750)
                                                          ________           ________           ________
                                                         8,246,871        (2,711,983)          5,534,888

Debt:
Finance leases                                            (16,891)             10,538            (6,353)
                                                          ________          _________            _______
Net funds                                                8,229,980        (2,701,445)          5,528,535
                                                         =========          =========          =========



C3 Reconciliation of net cash flow to movements in net funds

                                                                            2005                 2004
                                                                               £                    £

Increase / (decrease) in cash in the year                            (2,711,983)            8,180,923
Cash outflow from reduction in debt                                       10,538               20,212
New finance leases                                                             -              (6,764)
Exchange differences                                                           -             (26,647)
                                                                        ________             ________
Movement in net funds in the year                                    (2,701,445)            8,167,724
Opening net funds                                                      8,229,980               62,256
                                                                        ________             ________
Closing net funds                                                      5,528,535            8,229,980
                                                                       =========            =========


ANGLE PLC

NOTES TO THE FINANCIAL INFORMATION
FOR THE YEAR ENDED 30 APRIL 2005

The financial information set out above does not constitute the Company's
statutory financial statements for the year ended 30 April 2005 within the
meaning of section 240 of the Companies Act 1985 but are derived from the
audited financial statements.  The auditors have reported on these accounts and
their report was unqualified and did not contain statements under s237(2) or (3)
of the Companies Act 1985.

1              Basis of preparation

The financial information in this announcement has been prepared on the basis of
the accounting policies as set out in the financial statements for the year
ended 30 April 2004. The 2004 statutory accounts have been delivered to the
Registrar of Companies and the auditor's report on those accounts was
unqualified.

2       Compliance with accounting standards

         The Financial Statements are prepared in accordance with the Companies
Act 1985 and applicable United Kingdom accounting standards.

         The directors have, in accordance with sections 226 and 227 of the
Companies Act 1985, departed from the standard format of the profit and loss
account in presenting the financial statements.  Profits and losses on disposals
of fixed asset investments, and provisions for diminution in value of fixed
asset investments are included in 'Other operating income' within operating
profit as these represent a return from a principal class of business activity.
Other material disposals that are not part of the main business activities are
shown below operating profit in accordance with the Companies Act 1985 and FRS3
- Reporting Financial Performance. Examples of such material disposals include
fixed assets, such as property, or current asset investments, such as listed
shares held for disposal in the short term.

3       Tax

The Group is eligible for and takes advantage of the substantial shareholdings
relief UK corporation tax exemption.  This results in the gain from any
disposals of UK investments where the Group has an equity stake greater than
10%, and subject to certain other tests, being free of corporation tax.
Tax is therefore based on the net of profits in the Consulting and
Management businesses as relieved by losses incurred in the establishment and
development of new ventures.

4       Earnings per share

          The basic and fully diluted earnings per share is calculated on an
after tax loss of £2.32 million (2004: profit £2.29 million).

          The basic earnings per share is based on 16,697,500 weighted average
ordinary 10p shares (2004: 11,209,904).  Share options are non-dilutive for the
year because of the loss.  The fully diluted earnings per share is based on
16,697,500 weighted average ordinary 10p shares (2004:  11,775,197).

ANGLE PLC

NOTES TO THE FINANCIAL INFORMATION (Continued)
FOR THE YEAR ENDED 30 APRIL 2005

5       Reconciliation of movement in shareholders' funds


Group                                                                               2005              2004
                                                                                       £                 £

Profit / (loss) for the year                                                 (2,315,531)         2,290,620
Conversion of warrants                                                                 -            16,916
Gross proceeds from issue of shares                                               10,000         9,000,000
Issue expenses                                                                   (2,654)         (837,669)
Currency translation differences                                                (42,990)          (26,647)
                                                                               _________         _________
Net addition / (reduction) to shareholders' funds                            (2,351,175)        10,443,220

Opening shareholders' funds                                                   10,989,392           546,172
                                                                               _________         _________
Closing shareholders' funds                                                    8,638,217        10,989,392
                                                                              ==========         =========



6       Shareholder communications

Copies of this announcement are posted on the Company's website www.ANGLEplc.com
and are available from Buchanan Communications.

The Annual General Meeting of the Company will be held at 2 pm on 25 August 2005
at ANGLE's offices, Surrey Technology Centre, The Surrey Research Park,
Guildford, GU2 7YG.  Notice of the meeting will be enclosed with the audited
statutory financial statements.

The audited statutory financial statements for the year ended 30 April 2005 are
expected to be distributed to shareholders by 1 August 2005 and will
subsequently be available on the Company's website or from the registered
office, Surrey Technology Centre, Surrey Research Park, Guildford, GU2 7YG.

This preliminary announcement was approved by the Board on 5 July 2005.


                      This information is provided by RNS
            The company news service from the London Stock Exchange